The global Association of Contract Research Organizations has issued two new documents outlining industry best practices on decentralized clinical trials (DCTs), which have assumed a new level of importance in light of the COVID-19 pandemic.
ACRO hopes that the documents developed by its DCT working party – a quality-by-design manual and a complementary risk assessment considerations template – will “help mitigate uncertainty and reduce the hesitation that
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?